image
Palisade Bio, Inc. PALI
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 2.52
-3.82 %
$ 3.35 M
Market Cap
-0.11
P/E
1. INTRINSIC VALUE

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.[ Read More ]

The intrinsic value of one PALI stock under the base case scenario is HIDDEN Compared to the current market price of 2.52 USD, Palisade Bio, Inc. is HIDDEN

PALI Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart PALI

image
FINANCIALS
250 K REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 164.44%
5Years -0.78%
7Years 47.77%
10Years 8.56%
-13.1 M OPERATING INCOME
16.86%
Growth Rates
1Year 16.86%
3Years -12.02%
5Years -9.61%
7Years 6.01%
10Years -0.43%
-12.3 M NET INCOME
13.74%
Growth Rates
1Year 13.74%
3Years -6.02%
5Years -20.09%
7Years 7.40%
10Years 4.66%
-11.1 M OPERATING CASH FLOW
16.67%
Growth Rates
1Year 16.67%
3Years -32.67%
5Years -7.67%
7Years 4.72%
10Years -0.50%
-4 K INVESTING CASH FLOW
60.00%
Growth Rates
1Year 60.00%
3Years 12.64%
5Years -0.02%
7Years -0.02%
10Years 38.74%
11.2 M FINANCING CASH FLOW
-26.69%
Growth Rates
1Year -26.69%
3Years 80.89%
5Years 43.88%
7Years -10.19%
10Years -5.89%
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 164.44%
5Years -0.78%
7Years 47.77%
10Years 8.56%
-3.59 M OPERATING INCOME
14.68%
Growth Rates
1Year 16.86%
3Years -12.02%
5Years -9.61%
7Years 6.01%
10Years -0.43%
-3.49 M NET INCOME
14.53%
Growth Rates
1Year 13.74%
3Years -6.02%
5Years -20.09%
7Years 7.40%
10Years 4.66%
-3.13 M OPERATING CASH FLOW
10.46%
Growth Rates
1Year 16.67%
3Years -32.67%
5Years -7.67%
7Years 4.72%
10Years -0.50%
0 INVESTING CASH FLOW
0.00%
Growth Rates
1Year 60.00%
3Years 12.64%
5Years -0.02%
7Years -0.02%
10Years 38.74%
-180 K FINANCING CASH FLOW
-5.03%
Growth Rates
1Year -26.69%
3Years 80.89%
5Years 43.88%
7Years -10.19%
10Years -5.89%
Balance Sheet Decomposition Palisade Bio, Inc.
image
Current Assets 13.3 M
Cash & Short-Term Investments 12.4 M
Receivables 148 K
Other Current Assets 748 K
Non-Current Assets 724 K
Long-Term Investments 0
PP&E 208 K
Other Non-Current Assets 516 K
Current Liabilities 2.59 M
Accounts Payable 698 K
Short-Term Debt 279 K
Other Current Liabilities 1.61 M
Non-Current Liabilities 153 K
Long-Term Debt 90 K
Other Non-Current Liabilities 63 K
EFFICIENCY
Earnings Waterfall Palisade Bio, Inc.
image
Revenue 250 K
Cost Of Revenue 4 K
Gross Profit 246 K
Operating Expenses 13.3 M
Operating Income -13.1 M
Other Expenses -770 K
Net Income -12.3 M
RATIOS
98.40% GROSS MARGIN
98.40%
Averages
1Year 98.40%
3Years 32.80%
5Years -156.30%
7Years -28.67%
10Years 9.93%
-5228.00% OPERATING MARGIN
-5228.00%
Averages
1Year -5228.00%
3Years -1742.67%
5Years -26012.91%
7Years -19760.57%
10Years -53893.64%
-4920.00% NET MARGIN
-4920.00%
Averages
1Year -4920.00%
3Years -1640.00%
5Years -27470.62%
7Years -20753.22%
10Years -59582.02%
-108.72% ROE
-108.72%
Averages
1Year -108.72%
3Years -193.86%
5Years -136.17%
7Years -135.17%
10Years -168.07%
-87.53% ROA
-87.53%
Averages
1Year -87.53%
3Years -128.90%
5Years -172.73%
7Years -148.65%
10Years -134.95%
-113.94% ROIC
-113.94%
Averages
1Year -113.94%
3Years -264.39%
5Years -181.16%
7Years -178.54%
10Years -159.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Palisade Bio, Inc.
image
Net Income -12.3 M
Depreciation & Amortization 4 K
Capital Expenditures -4 K
Stock-Based Compensation 624 K
Change in Working Capital 400 K
Others 1.03 M
Free Cash Flow -11.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Palisade Bio, Inc.
image
PALI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

image
3.02 USD
ZURA
Overvalued 4.48%

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.

image
1.19 USD
CYTO
Undervalued 160.42%

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia.

image
1.01 USD
IMMX
Overvalued 36.50%

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy.

image
1.06 USD
ENVB
Undervalued 190.33%

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.

image
-2.09 USD
EFTR
Overvalued 1044932.22%

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases.

image
3.21 USD
ZVSA
Undervalued 197.14%

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system.

image
4.06 USD
PHIO
Undervalued 83.62%

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury.

image
0.392 USD
UNCY
Overvalued 14.78%
6. Ownership
Insider Ownership Palisade Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
9.67 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
16.3 K USD 2
9-12 MONTHS
Date Value Insider Amount Avg Price
5 months ago
May 28, 2024
Bought 4.86 K USD
Williams Donald Allen
Director
+ 1000
 4.863 USD
5 months ago
May 24, 2024
Bought 4.81 K USD
Finley John David
CEO, CFO, Director
+ 1000
 4.81 USD
9 months ago
Feb 06, 2024
Bought 4.69 K USD
Finley John David
CEO, CFO, Director
+ 10000
 0.4692 USD
9 months ago
Jan 31, 2024
Bought 5.59 K USD
Finley John David
CEO, CFO, Director
+ 10000
 0.559 USD
9 months ago
Jan 31, 2024
Bought 6.05 K USD
Williams Donald Allen
Director
+ 10000
 0.605 USD
1 year ago
Sep 27, 2023
Bought 10.8 K USD
Williams Donald Allen
Director
+ 20000
 0.54 USD
1 year ago
Sep 27, 2023
Bought 8.09 K USD
Finley John David
CEO, CFO, Director
+ 15000
 0.5392 USD
1 year ago
Sep 14, 2023
Sell 192 USD
Trenschel Robert J.
Director
- 300
 0.64 USD
1 year ago
Sep 13, 2023
Bought 9.82 K USD
Finley John David
CEO, CFO, Director
+ 15000
 0.655 USD
2 years ago
Sep 01, 2022
Bought 2.8 K USD
Finley John David
Chief Financial Officer
+ 19481.242
 0.1437 USD
2 years ago
Aug 23, 2022
Bought 1.18 K USD
Finley John David
Chief Financial Officer
+ 7350
 0.16 USD
2 years ago
Aug 16, 2022
Bought 0 USD
Hallam Thomas
Chief Executive Officer
+ 40000
 0 USD
2 years ago
Aug 16, 2022
Bought 0 USD
Finley John David
Chief Financial Officer
+ 100000
 0 USD
2 years ago
Mar 29, 2022
Bought 17.1 K USD
Dawson Michael John
Chief Medical Officer
+ 15000
 1.1395 USD
2 years ago
Mar 28, 2022
Bought 11.8 K USD
Hallam Thomas
Chief Executive Officer
+ 10000
 1.18 USD
2 years ago
Mar 24, 2022
Bought 8.17 K USD
Finley John David
Chief Financial Officer
+ 7500
 1.0899 USD
3 years ago
Sep 21, 2021
Bought 4.88 K USD
Finley John David
Chief Financial Officer
+ 2000
 2.44 USD
3 years ago
Sep 21, 2021
Bought 14.9 K USD
Hallam Thomas
Chief Executive Officer
+ 6000
 2.49 USD
3 years ago
Sep 10, 2021
Bought 6.38 K USD
Trenschel Robert J.
Director
+ 2142
 2.98 USD
3 years ago
Sep 09, 2021
Bought 9.83 K USD
Trenschel Robert J.
Director
+ 3400
 2.89 USD
3 years ago
Sep 08, 2021
Bought 13.8 K USD
Trenschel Robert J.
Director
+ 5000
 2.75 USD
3 years ago
Sep 07, 2021
Bought 7.53 K USD
Trenschel Robert J.
Director
+ 2707
 2.78 USD
3 years ago
Aug 31, 2021
Bought 4.81 K USD
Trenschel Robert J.
Director
+ 1750
 2.75 USD
3 years ago
Aug 27, 2021
Bought 22.3 K USD
Finley John David
Chief Financial Officer
+ 8400
 2.65 USD
3 years ago
Aug 27, 2021
Bought 4.21 K USD
Finley John David
Chief Financial Officer
+ 1600
 2.63 USD
7 years ago
May 17, 2017
Bought 30 K USD
Daly Richard J
Chief Executive Officer
+ 7500
 4 USD
7 years ago
Mar 24, 2017
Bought 30 K USD
LLOYD JONES JONATHAN BRIAN
Chief Financial Officer
+ 5455
 5.5 USD
7 years ago
Feb 24, 2017
Bought 10 K USD
Daly Richard J
Chief Executive Officer
+ 2591
 3.86 USD
7 years ago
Jan 25, 2017
Bought 10 K USD
Daly Richard J
Chief Executive Officer
+ 2841
 3.52 USD
7 years ago
Dec 23, 2016
Bought 10 K USD
Daly Richard J
Chief Executive Officer
+ 32259
 0.31 USD
7 years ago
Nov 25, 2016
Bought 10 K USD
Daly Richard J
Chief Executive Officer
+ 35715
 0.28 USD
8 years ago
Oct 25, 2016
Bought 10 K USD
Daly Richard J
Chief Executive Officer
+ 35715
 0.28 USD
8 years ago
Sep 23, 2016
Bought 10 K USD
LLOYD JONES JONATHAN BRIAN
Chief Financial Officer
+ 31250
 0.32 USD
8 years ago
Sep 23, 2016
Bought 10 K USD
Daly Richard J
Chief Executive Officer
+ 31250
 0.32 USD
9 years ago
Nov 16, 2015
Sell 27.3 K USD
JOHE KARL
Chief Scientific Officer
- 25000
 1.09 USD
9 years ago
Nov 09, 2015
Sell 29.5 K USD
JOHE KARL
Chief Scientific Officer
- 25000
 1.18 USD
9 years ago
Nov 02, 2015
Sell 29.4 K USD
JOHE KARL
Chief Scientific Officer
- 25000
 1.1742 USD
9 years ago
Oct 26, 2015
Sell 28.2 K USD
JOHE KARL
Chief Scientific Officer
- 25000
 1.1276 USD
9 years ago
Oct 19, 2015
Sell 30.7 K USD
JOHE KARL
Chief Scientific Officer
- 25000
 1.2276 USD
9 years ago
Oct 12, 2015
Sell 32.7 K USD
JOHE KARL
Chief Scientific Officer
- 25000
 1.309 USD
9 years ago
Oct 05, 2015
Sell 31.5 K USD
JOHE KARL
Chief Scientific Officer
- 25000
 1.2584 USD
9 years ago
Sep 28, 2015
Sell 41 K USD
JOHE KARL
Chief Scientific Officer
- 25000
 1.64 USD
9 years ago
Sep 21, 2015
Sell 38.1 K USD
JOHE KARL
Chief Scientific Officer
- 25000
 1.5231 USD
10 years ago
Sep 02, 2014
Sell 24.5 K USD
JOHE KARL
Chief Scientific Officer
- 6000
 4.09 USD
10 years ago
Aug 01, 2014
Sell 16.7 K USD
JOHE KARL
Chief Scientific Officer
- 6000
 2.78 USD
10 years ago
Jul 01, 2014
Sell 25 K USD
JOHE KARL
Chief Scientific Officer
- 6000
 4.17 USD
10 years ago
Jun 02, 2014
Sell 25.5 K USD
JOHE KARL
Chief Scientific Officer
- 6000
 4.25 USD
10 years ago
May 05, 2014
Bought 49.9 K USD
OLDAKER WILLIAM CLYDE
Director
+ 14250
 3.4999 USD
10 years ago
May 05, 2014
Bought 3.45 K USD
OLDAKER WILLIAM CLYDE
Director
+ 985
 3.5 USD
10 years ago
May 01, 2014
Sell 21.3 K USD
JOHE KARL
Chief Scientific Officer
- 6000
 3.5425 USD
10 years ago
Apr 22, 2014
Sell 29.8 K USD
GARR RICHARD
CEO
- 7000
 4.25 USD
10 years ago
Apr 01, 2014
Sell 24.6 K USD
JOHE KARL
Chief Scientific Officer
- 6000
 4.1063 USD
10 years ago
Mar 20, 2014
Sell 24.2 K USD
JOHE KARL
Chief Scientific Officer
- 6000
 4.0415 USD
11 years ago
Oct 21, 2013
Sell 23.5 K USD
JOHE KARL
Chief Scientific Officer
- 10000
 2.3458 USD
11 years ago
Oct 18, 2013
Sell 24.4 K USD
JOHE KARL
Chief Scientific Officer
- 10000
 2.4446 USD
11 years ago
Sep 20, 2013
Sell 26.2 K USD
JOHE KARL
Chief Scientific Officer
- 10000
 2.6241 USD
11 years ago
Sep 19, 2013
Sell 26.1 K USD
JOHE KARL
Chief Scientific Officer
- 10000
 2.6094 USD
11 years ago
Aug 20, 2013
Sell 31 K USD
JOHE KARL
Chief Scientific Officer
- 20000
 1.5493 USD
11 years ago
Jul 22, 2013
Sell 20.8 K USD
JOHE KARL
Chief Scientific Officer
- 12800
 1.6234 USD
11 years ago
Jun 20, 2013
Sell 17.9 K USD
JOHE KARL
Chief Scientific Officer
- 12800
 1.395 USD
11 years ago
Jun 07, 2013
Sell 8.52 K USD
GARR RICHARD
CEO
- 6000
 1.42 USD
11 years ago
May 20, 2013
Sell 19.3 K USD
JOHE KARL
Chief Scientific Officer
- 12800
 1.5079 USD
11 years ago
Apr 22, 2013
Sell 14.5 K USD
JOHE KARL
Chief Scientific Officer
- 12800
 1.1344 USD
11 years ago
Mar 20, 2013
Sell 14.5 K USD
JOHE KARL
Chief Scientific Officer
- 12800
 1.1364 USD
11 years ago
Feb 25, 2013
Sell 13.8 K USD
GARR RICHARD
CEO
- 12000
 1.15 USD
11 years ago
Feb 20, 2013
Sell 15.1 K USD
JOHE KARL
Chief Scientific Officer
- 12800
 1.18 USD
11 years ago
Jan 22, 2013
Sell 16.3 K USD
JOHE KARL
Chief Scientific Officer
- 12800
 1.27 USD
11 years ago
Dec 20, 2012
Sell 14.8 K USD
JOHE KARL
Chief Scientific Officer
- 12800
 1.158 USD
11 years ago
Nov 20, 2012
Sell 12.8 K USD
JOHE KARL
Chief Scientific Officer
- 12800
 1 USD
14 years ago
Sep 16, 2010
Bought 5.78 K USD
OLDAKER WILLIAM CLYDE
Director
+ 2500
 2.31 USD
14 years ago
Sep 16, 2010
Bought 17.4 K USD
OLDAKER WILLIAM CLYDE
Director
+ 7500
 2.32 USD
14 years ago
Dec 30, 2009
Bought 312 K USD
GARR RICHARD
CEO
+ 189111
 1.65 USD
14 years ago
Dec 30, 2009
Bought 60 K USD
CONRON JOHN
Chief Financial Officer
+ 36364
 1.65 USD
16 years ago
Aug 21, 2008
Bought 3.89 K USD
OLDAKER WILLIAM CLYDE
Director
+ 2200
 1.77 USD
16 years ago
Aug 21, 2008
Bought 5.37 K USD
OLDAKER WILLIAM CLYDE
Director
+ 3000
 1.79 USD
16 years ago
Aug 21, 2008
Bought 910 USD
OLDAKER WILLIAM CLYDE
Director
+ 500
 1.82 USD
16 years ago
Aug 21, 2008
Bought 2.74 K USD
OLDAKER WILLIAM CLYDE
Director
+ 1500
 1.83 USD
16 years ago
Aug 21, 2008
Bought 5.61 K USD
OLDAKER WILLIAM CLYDE
Director
+ 3000
 1.87 USD
16 years ago
Aug 21, 2008
Bought 3.89 K USD
OLDAKER WILLIAM CLYDE
Director
+ 2200
 1.77 USD
16 years ago
Aug 21, 2008
Bought 5.37 K USD
OLDAKER WILLIAM CLYDE
Director
+ 3000
 1.79 USD
16 years ago
Aug 21, 2008
Bought 910 USD
OLDAKER WILLIAM CLYDE
Director
+ 500
 1.82 USD
16 years ago
Aug 21, 2008
Bought 2.74 K USD
OLDAKER WILLIAM CLYDE
Director
+ 1500
 1.83 USD
16 years ago
Aug 21, 2008
Bought 5.61 K USD
OLDAKER WILLIAM CLYDE
Director
+ 3000
 1.87 USD
16 years ago
Jul 10, 2008
Bought 2.48 K USD
CONRON JOHN
Chief Financial Officer
+ 1700
 1.46 USD
16 years ago
Jul 10, 2008
Bought 715 USD
CONRON JOHN
Chief Financial Officer
+ 500
 1.43 USD
16 years ago
Jul 10, 2008
Bought 846 USD
CONRON JOHN
Chief Financial Officer
+ 600
 1.41 USD
16 years ago
Jul 10, 2008
Bought 875 USD
CONRON JOHN
Chief Financial Officer
+ 625
 1.4 USD
16 years ago
Jul 10, 2008
Bought 1.36 K USD
CONRON JOHN
Chief Financial Officer
+ 1000
 1.36 USD
16 years ago
Jul 10, 2008
Bought 135 USD
CONRON JOHN
Chief Financial Officer
+ 100
 1.35 USD
16 years ago
Jul 10, 2008
Bought 627 USD
CONRON JOHN
Chief Financial Officer
+ 475
 1.32 USD
16 years ago
Jul 07, 2008
Bought 69.6 K USD
GARR RICHARD
CEO, President
+ 49000
 1.42 USD
16 years ago
Jun 03, 2008
Bought 19.5 K USD
OLDAKER WILLIAM CLYDE
Director
+ 10000
 1.95 USD
16 years ago
May 30, 2008
Bought 16 K USD
OLDAKER WILLIAM CLYDE
Director
+ 10000
 1.6 USD
16 years ago
Feb 08, 2008
Bought 29.2 K USD
OLDAKER WILLIAM CLYDE
Director
+ 9700
 3.0128 USD
17 years ago
Sep 19, 2007
Bought 22.5 K USD
OLDAKER WILLIAM CLYDE
Director
+ 7500
 2.997 USD
17 years ago
Apr 17, 2007
Bought 35 K USD
CONRON JOHN
Chief Financial Officer
+ 10000
 3.5 USD
7. News
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108 Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) globenewswire.com - 4 days ago
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company dedicated to developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases has announced the presentation of data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood. This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC). globenewswire.com - 2 weeks ago
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) – Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) globenewswire.com - 1 month ago
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update – Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end globenewswire.com - 3 months ago
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis – Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end globenewswire.com - 3 months ago
Palisade Bio Participates in Virtual Investor “What this Means” Segment Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108 globenewswire.com - 3 months ago
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients globenewswire.com - 3 months ago
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition of Matter coverage beyond 2042 PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis (UC) PALI-1908 is in development to treat patients with active fibro stenotic Crohn's Disease (CD) Carlsbad, CA, July 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that European Patent Office (EPO) has issued a decision to grant notice for patent number 4,157,853 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” Based on the intention to grant notice, the Company expects the EPO to issue a patent July 31, 2024. globenewswire.com - 3 months ago
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) before year end Carlsbad, CA, July 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of the first Good Manufacturing Practice (GMP) batch of its drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC. The GMP manufacturing was conducted in partnership with Eurofins, a contract development and manufacturing organization. globenewswire.com - 4 months ago
Palisade Bio to Participate in the Virtual Investor Closing Bell Series Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET. As part of the event, J.D. globenewswire.com - 4 months ago
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences – Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics globenewswire.com - 4 months ago
Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 5 months ago
8. Profile Summary

Palisade Bio, Inc. PALI

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.35 M
Dividend Yield 0.00%
Description Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Contact 5800 Armada Drive, Carlsbad, CA, 92008 https://www.palisadebio.com
IPO Date March 30, 2007
Employees 9
Officers Dr. Joerg Heyer Ph.D. Head of Translational Science & Medicine Mr. J. D. Finley Chief Executive Officer, Chief Financial Officer & Director Mr. Ryker Willie Senior Vice President of Finance & Corporate Controller Dr. Mitchell Lawrence Jones M.D., Ph.D. Chief Operating Officer & Chief Medical Officer